Falcon Vision LLC 3
3 · Oyster Point Pharma, Inc. · Filed Oct 30, 2019
Insider Transaction Report
Form 3
Falcon Vision LLC
10% Owner
Holdings
- (indirect: See footnotes)
Series B Convertible Preferred Stock
→ Common Stock, par value $0.001 per share (884,622 underlying)
Footnotes (3)
- [F1]These shares of Series B Convertible Preferred Stock will automatically be converted into shares of the Issuer's Common Stock, on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock has no expiration date.
- [F2]The securities reported herein are held by Falcon Vision LLC. KKR Health Care Strategic Growth Fund L.P., as the managing member of Falcon Vision LLC, KKR Associates HCSG L.P., as the general partner of KKR Health Care Strategic Growth Fund L.P., KKR HCSG GP LLC, as the general partner of KKR Associates HCSG L.P., KKR Fund Holdings L.P., as the sole member of KKR HCSG GP LLC, KKR Fund Holdings GP Limited, as a general partner of KKR Fund Holdings L.P., KKR Group Holdings Corp., as a general partner of KKR Fund Holdings L.P. and the sole shareholder of KKR Fund Holdings GP Limited, KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described in this footnote.
- [F3]Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by Falcon Vision LLC.